Eli Lilly has followed Novo Nordisk in announcing a big investment in its manufacturing network, intended to meet anticipated strong future demand for diabetes and obesity
Novo Nordisk is leaving nothing to chance when it comes to claiming a stake in the burgeoning market for diabetes and obesity therapies, announcing a plan to spend a whopp
Shares in EuroAPI, the active pharmaceutical ingredients (API) business spun out of Sanofi last year, have fallen sharply on the back of a sharp slowdown in sales.